The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
"Dopamine System Stabilizers, Aripiprazole, and the Next Generation of Antipsychotics, Part 1: "Goldilocks" Actions at Dopamine Receptors: (Brainstorms)
Open accessAbstract
Article AbstractBrainstorms: Psychosis occurs when too much dopamine exists in the synapses, and the action, akin to Goldilocks's first bowl of soup, is "too hot." Every antipsychotic that reduces the positive symptoms of psychosis such as delusions and hallucinations does so by blocking dopamine D2 receptors, most likely those of the mesolimbic dopamine pathway. Unfortunately, the blocking is often nonspecific, which is typical of conventional antipsychotic actions. Thus, when D2 receptors in the nigrostriatal dopamine pathway are also blocked, a penalty is paid in motor side effects, namely extrapyramidal reactions, pseudoparkinsonism, and ultimately, tardive dyskinesia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, third-generation antipsychotics, such as aripiprizole, are partial D2 receptor agonists with high affinity and low intrinsic activity, and these drugs may act as ‘DA stabilizers’ because of their ability to stabilize, rather than simply upregulate or downregulate functional output of DA systems [428].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [428]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vliet, B. J. V., Ronken, E., Tulp, M. T. M., Feenstra, R., Kruse, C. G., & Long, S. K. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80319-3 · Cited by 12
Research works printed but not linked: 6
- Stahl SM. Essential Psychopharma- cology. 2nd ed. New York, NY: Cambridge University Press; 2000
- Carlsson A, Waters N, Carlson ML. Biol Psychiatry 1999;46:1388-1395
- Toru M, Miura S, Kudo Y. Neuro- psychopharmacology 1994;10:122S
- Lawler CP, Prioleau C, Lewis MM, et al. Neuropsychopharmacology 1999; 20:612-627
- Ekesbo A, Andren PE, Gunne LM, et al. NeuroReport 1997;8:2567-2570
- Lahti AC, Weiler MA, Corey PK, et al. Biol Psychiatry 1998;43:2-11 The author gratefully acknowledges the review of this feature by Herbert Y. Meltzer, M.D.; Terrance H. Andree, Ph.D.; and Robert McQuaid, Ph.D.
Cited by
Sorted by citations
Items 101–142 of 142
Key issues and unmet needs in schizophrenia
Stahl, S. M. (2003) · CRC Press eBooks · doi:10.3109/9780203427347-13 · Cited by 5
Self-citationAripiprazole Therapy for Nicotine Dependence
Ramaswamy, S. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0109b · Cited by 5
Partial agonists and suicide: the role of the mental health nurse
Jones, M., & Gray, R. J. (2008) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/j.1365-2850.2007.01189.x · Cited by 5
Husak, N., Laudone, T. W., & Leonard, J. B. (2023) · Clinical Toxicology · doi:10.1080/15563650.2022.2163901 · Cited by 4
The action of aripiprazole and brexpiprazole at the receptor level in singultus
Alefishat, E. A., Aloum, L., Baltatu, O. C., & Petroianu, G. A. (2021) · Journal of Integrative Neuroscience · doi:10.31083/j.jin.2021.01.273 · Cited by 4
A UK panel consensus on the initiation of aripiprazole for the treatment of bipolar mania
Dratcu, L., Bobmanuel, S., Davies, W. C., Farmer, A., George, M., Rana, T., Singh, M., & Turner, M. R. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.709865 · Cited by 5
An Open-Label Study of Aripiprazole for Methamphetamine Induced Psychosis
Sulaiman, A. H., Gill, J. S., Said, M. A., Habil, M. H., Zainal, N. Z., & Ng, C. G. (2012) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20120412020813 · Cited by 4
Lee, B. J. (2016) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20150908025240 · Cited by 4
Suzuki, M., Niidome, K., Maeda, K., Kikuchi, T., Usami, T., & Futamura, T. (2019) · Folia Pharmacologica Japonica · doi:10.1254/fpj.154.275 · Cited by 3
Reist, C., Albers, L. J., Marder, S. R., Williams–Jones, B., Wu, J. C., Mee, S., Shimoda, K., Someya, T., & Özdemir, V. (2005) · Current Pharmacogenomics · doi:10.2174/157016005774913194 · Cited by 3
Prescription Dose Analysis of Quetiapine in the Elderly and Insomnia
Lee, K. Y., Ryu, S., Ha, J. H., Jeon, H. J., & Park, D. (2021) · Chronobiology in Medicine · doi:10.33069/cim.2021.0031 · Cited by 4
Cerebellum and Schizophrenia – The Cerebellum Volume Reduction Theory of Schizophrenia
Okugawa, G. (2012) · Springer eBooks · doi:10.1007/978-94-007-1333-8_88 · Cited by 3
Functional Selectivity at Dopamine Receptors
Mailman, R. B., Wang, Y., Kant, A., & Brown, J. T. (2009) · The Receptors · doi:10.1007/978-1-60327-335-0_10 · Cited by 3
Le, V., Surineni, K., & Preskorn, S. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002103 · Cited by 2
Aripiprazole: An Antipsychotic with a Novel Mechanism of Action
Lemieux, A. A., Goldman, J. D., & Gören, J. L. (2003) · Journal of Pharmacy Technology · doi:10.1177/875512250301900606 · Cited by 2
Tourian, L., & Margolese, H. C. (2013) · Neuropsychiatry · doi:10.2217/npy.13.7 · Cited by 2
Cariprazine for late-life psychiatric illness
Mukku, S. S. R., Nadella, R. K., & Kornapalli, S. E. (2021) · Journal of Geriatric Mental Health · doi:10.4103/jgmh.jgmh_43_21 · Cited by 2
Oculogyric Crisis Associated With Clozapine: Case Report and Review of Literature
Shukla, R., & Thomas, A. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001960 · Cited by 2
Aripiprazole: examining the clinical implications of D2 affinity
Anam, A., Lynch, S. T., Mosharraf, N., Soukas, C., & Gekhman, D. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000435 · Cited by 3
2-Bromoterguride–a potential atypical antipsychotic drug without metabolic effects in rats
Franke, R. T., Tarland, E., Fink, H., Pertz, H. H., & Brosda, J. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4356-0 · Cited by 3
Ismail, N. E., Jha, A. N., Goh, K. W., Ming, L. C., Wahab, M. S. A., Shah, N. J., Shah, A. H., & Hermansyah, A. (2022) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.1177/0976500x221142377 · Cited by 2
Aripiprazole: an appraisal of the translation of complex receptor effects into clinical outcomes
Buckley, P. F., & Sebastian, S. (2005) · Therapy · doi:10.1586/14750708.2.5.699 · Cited by 2
Treating Bipolar Disorder in the Primary Care Setting
Manning, J. S., & McElroy, S. L. (2009) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.08r00635 · Cited by 2
Li, B., Zhu, J., Zhang, B., Ling, Z., Zhao, Y., Leng, W., Zhang, Q., & Zhou, X. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s543465 · Cited by 1
Mao, Z., Dong, F., Li, A., Li, F., Zhu, J., Du, X., Wu, G., Deng, H., Xue-qin, Y., Liu, J., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06455-y · Cited by 1
Rapagnani, M. P. (2012) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s7388 · Cited by 1
Is Aripiprazole Useful to Refrain From Cocaine Use After Detoxification (Avoiding Relapses)?
Cassano, G. B., Lattanzi, L., Litta, A., Lombardi, V., Tatulli, A., Benedetti, A., Longobardi, A., & Maremmani, I. (2009) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0b013e318195001f · Cited by 1
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00025-1 · Cited by 1
Eren, İ., Demirdaş, A., & İnanlı, İ. (2014) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20130313045200 · Cited by 1
Vercammen, A. (2009) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 1
The Evolving Paradigm for Bipolar Disorder
Keck, P. E., Sachs, G. S., & Vieta, E. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0119 · Cited by 1
Bluetooth scatternet formation algorithm
Rao., S. B. S. N. (2004) · DR-NTU (Nanyang Technological University) · Cited by 1
Chemical Perspective on Neurotransmission and Drug Discovery for the Central Nervous System
Mailman, R. B., & Vrana, K. E. (2010) · Burger's Medicinal Chemistry and Drug Discovery · doi:10.1002/0471266949.bmc245
Dopamine D2 Receptor Functional Selectivity as a Mechanism of Atypical Antipsychotic Drug Action
Urban, J. D. (2006) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/q8t3-p159 · Cited by 1
Lee, L. H. N. (2019) · cIRcle (University of British Columbia) · doi:10.14288/1.0349186
Neurobiology of Eating Disorders and the Use of Psychotropic Medications
McShane, K. M., & Ozbolt, L. B. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180912-01
Tratamiento antipsicótico en la esquizofrenia: las opciones atípicas y la guía NICE
Mortimer, A. M. (2003) · European psychiatry (Ed Española) · doi:10.1017/s1134066500007840
“Aripiprazole, A New Generation Antipsychotic: Current Research and Clinical Practice
Singh, G., Loona, N., & Singla, R. K. (2021) · Eastern Journal of Psychiatry · doi:10.5005/ejp-16-1--2-1
Carvajal, A., Arias, L. H. M., & Bulnes, N. J. (2009) · Side effects of drugs annual · doi:10.1016/s0378-6080(09)03106-7
Vardanyan, R., & Vardanyan, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33869-4.00037-5
Connecting the dots : new perspectives on stress and psychosis
Lataster, J. (2012) · Research Publications (Maastricht University) · doi:10.26481/dis.20120127jl
Chen, H., Lai, T., Jin, W., Xia, H., & Sun, F. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1857010
Metadata
- Authors
- Stahl, S. M.
- Affiliations
- Neuroscience Education Institute (US)
- Corresponding author
- Stahl, Stephen M.
- ORCID
- Stahl, Stephen M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2001-11-15
- Volume
- 62
- Issue
- 11
- Pages
- 841-842
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2091915431
- Cited by
- 143
- References
- 1
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 2 · 2023: 6 · 2022: 8 · 2021: 6 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 1 · 2016: 5 · 2015: 2 · 2014: 6 · 2013: 3 · 2012: 10
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- aripiprazole, dopamine D2 receptor, dopamine agonists, antipsychotic drugs, psychosis, mesolimbic dopamine system, nigrostriatal dopamine pathway, extrapyramidal symptoms, tardive dyskinesia, positive symptoms
- MeSH terms
- Aripiprazole, Binding Sites, Corpus Striatum, Humans, Piperazines, Psychotic Disorders, Substantia Nigra, Antipsychotic Agents, Dopamine Agents, Quinolones, Receptors, Dopamine D2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
